Top

Published in:

01-05-2009 | Personal View

Pharmacologic treatment to prevent fractures: from markers to patients

Author: Steven R. Cummings

Published in: Osteoporosis International | Special Issue 3/2009

Excerpt

Pierre Delmas made fundamental contributions to our understanding of the mechanisms of action of treatments for osteoporosis, played an important role in the design and publication of most of the agents in our armamentarium of treatments for osteoporosis, and provided evidence and guidance about the use of markers of bone turnover in clinical practice. …

Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337(23):1641-1647CrossRefPubMed

Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87(8):3609-3617CrossRefPubMed

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637-645CrossRefPubMed

Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112(4):281-289CrossRefPubMed

Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34(4):599-604CrossRefPubMed

Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12(11):922-930CrossRefPubMed

Delmas PD (2000) How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27(1):1-3CrossRefPubMed

Bauer D, Black D, Garnero P, Hochberg M, Ott S, Schneider D, Orloff J, Thompson D, Ewing S, Delmas P (2002) Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial. J Bone Miner Res

Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359(9322):2018-2026CrossRefPubMed

Title: Pharmacologic treatment to prevent fractures: from markers to patients
Author: Steven R. Cummings
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue Special Issue 3/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0914-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pharmacologic treatment to prevent fractures: from markers to patients

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 3/2009

Translational aspects of bone quality—vertebral fractures, cortical shell, microdamage and glycation: a tribute to Pierre D. Delmas

Festschrift to honor Professor Pierre D. Delmas

Bone histomorphometry and bone quality

Bone turnover markers: a key tool for understanding osteoporosis

The International Osteoporosis Foundation: history, objectives and achievements

How basic science informed the Delmas clinical approach